(Press-News.org) The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.
In their new study, reported in the July 30 issue of the journal Circulation, scientists demonstrated that gene therapy administered through a nebulizer-like inhalation device can completely reverse PAH in rat models of the disease. In the lab, researchers also showed in pulmonary artery PAH patient tissue samples reduced expression of the SERCA2a, an enzyme critical for proper pumping of calcium in calcium compartments within the cells. SERCA2a gene therapy could be sought as a promising therapeutic intervention in PAH.
"The gene therapy could be delivered very easily to patients through simple inhalation -- just like the way nebulizers work to treat asthma," says study co-senior investigator Roger J. Hajjar, MD, Director of the Cardiovascular Research Center and the Arthur & Janet C. Ross Professor of Medicine and Professor of Gene & Cell at Icahn School of Medicine at Mount Sinai. "We are excited about testing this therapy in PAH patients who are in critical need of intervention."
This same SERCA2a dysfunction also occurs in heart failure. This new study utilizes the same gene therapy currently being tested in patients to reverse congestive heart failure in a large phase III clinical trial in the United States and Europe.
"What we have shown is that gene therapy restores function of this crucial enzyme in diseased lungs," says Dr. Hajjar. "We are delighted with these new findings because it suggests that a gene therapy that is already showing great benefit in congestive heart failure patients may be able to help PAH patients who currently have no good treatment options — and are in critical need of a life sustaining therapy."
When SERCA2a is down-regulated, calcium stays longer in the cells than it should, and it induces pathways that lead to overgrowth of new and enlarged cells. According to researchers, the delivery of the SERCA2a gene produces SERCA2a enzymes, which helps both heart and lung cells restore their proper use of calcium.
"We are now on a path toward PAH patient clinical trials in the near future," says Dr. Hajjar, who developed the gene therapy approach. Studies in large animal models are now underway. SERCA2a gene therapy has already been approved by the National Institutes of Health for human study.
A Simple Inhalation Corrects Deadly Dysfunction
PAH most commonly results from heart failure in the left side of the heart or from a pulmonary embolism, when clots in the legs travel to the lungs and cause blockages. When the lung is damaged from these conditions, the tissue starts to quickly produce new and enlarged cells, which narrows pulmonary arteries. This increases the pressure inside them. The high pressure in these arteries resists the heart's effort to pump through them and the blood flow between the heart and lungs is reduced. The right side of the heart then must overcome the resistance and work harder to push the blood through the pulmonary arteries into the lungs. Over time, the right ventricle becomes thickened and enlarged and heart failure develops.
The gene therapy that Dr. Hajjar developed uses a modified adeno-associated viral-vector that is derived from a parvovirus. It works by introducing a healthy SERCA2a gene into cells, but this gene does not incorporate into a patient's chromosome, according to the study's lead author, Lahouaria Hadri, PhD, an Instructor of Medicine in Cardiology at Icahn School of Medicine at Mount Sinai.
"The clinical trials in congestive heart failure have shown already that the gene therapy is very safe," says Dr. Hadri. Between 40-50 percent of individuals have antecedent antibodies to the adeno-associated vectors, so potential patients need to be screened before gene therapy to make sure they are eligible to receive the vectors. In patients without antibodies, the restorative enzyme gene therapy does not cause an immune response, according to Dr. Hadri.
The clinical application of the gene therapy for patients with PAH will most likely differ from those with heart failure. The replacement gene needs to be injected through the coronary arteries of heart failure patients using catheters, while in PAH patients, the gene will need to be administered through inhalation.
###
This study was supported by National Institutes of Health grants (K01HL103176, K08111207, R01 HL078691, HL057263, HL071763, HL080498, HL083156, and R01 HL105301).
Other study co-authors include Razmig G. Kratlian, MD, Ludovic Benard, PhD, Kiyotake Ishikawa, MD, Jaume Aguero, MD, Dennis Ladage, MD, Irene C.Turnbull, MD, Erik Kohlbrenner, BA, Lifan Liang, MD, Jean-Sébastien Hulot, MD, PhD, and Yoshiaki Kawase, MD, from Icahn School of Medicine at Mount Sinai; Bradley A. Maron, MD and the study's co-senior author Jane A. Leopold, MD, from Brigham and Women's Hospital and Harvard Medical School in Boston, MA; Christophe Guignabert, PhD, from Hôpital Antoine-Béclère, Clamart, France; Peter Dorfmüller, MD, PhD, and Marc Humbert, MD, PhD, both of the Hôpital Antoine-Béclère and INSERM U999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France; Borja Ibanez, MD, from Fundación Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC), Madrid, Spain; and Krisztina Zsebo, PhD, of Celladon Corporation, San Diego, CA.
Dr. Hajjar and co-author Dr. Zsebo, have ownership interest in Celladon Corporation, which is developing AAV1.SERCA2a for the treatment of heart failure. Also, Dr. Hajjar and co-authors Dr. Kawase and Dr. Ladage hold intellectual property around SERCA2a gene transfer as a treatment modality for PAH. In addition, co-author Dr. Maron receives funding from Gilead Sciences, Inc. to study experimental pulmonary hypertension. Other study co-authors have no financial interests to declare.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine at Mount Sinai is one of the leading medical schools in the United States. The Icahn School of Medicine is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty members in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of just 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.
For more information, visit http://www.mountsinai.org.
Find Mount Sinai on:
Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy
Inhalable gene therapy may help pulmonary arterial hypertension patients
Gene therapy when inhaled may restore function of a crucial enzyme in the lungs to reverse deadly PAH
2013-07-30
ELSE PRESS RELEASES FROM THIS DATE:
AGU journal highlights -- July 30, 2013
2013-07-30
The following highlights summarize research papers that have been recently published in Geophysical Research Letters (GRL) and Journal of Geophysical Research-Solid Earth (JGR-B).
In this release:
1. Atmospheric rivers linked to severe precipitation in Western Europe
2. Warming climate increases rainfall extremes
3. Carbon fertilization increased arid region leaf cover over past 20 years
4. Understanding the complexities of volcanoes that erupt just once
5. Revealing the early seafloor spreading history between India and Australia
6. Independent observations corroborate ...
Water clears path for nanoribbon development
2013-07-30
HOUSTON – (July 30, 2013) – New research at Rice University shows how water makes it practical to form long graphene nanoribbons less than 10 nanometers wide.
And it's unlikely that many of the other labs currently trying to harness the potential of graphene, a single-atom sheet of carbon, for microelectronics would have come up with the technique the Rice researchers found while they were looking for something else.
The discovery by lead author Vera Abramova and co-author Alexander Slesarev, both graduate students in the lab of Rice chemist James Tour, appears online ...
Lessons from combat care helped save lives and limbs after Boston bombing, reports
2013-07-30
Philadelphia, Pa. -- Collaboration across surgical specialties and lessons from combat casualty care—especially the use of tourniquets and other effective strategies to control bleeding—helped mount an effective surgical response to aid victims of the Boston Marathon bombings, according to a special editorial in the July issue of The Journal of Craniofacial Surgery, which is led by Editor-in-Chief Mutaz B. Habal, MD, and published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
The experience of surgeons treating victims of the Boston bombings at Brigham ...
Full body illusion is associated with a drop in skin temperature
2013-07-30
Researchers from the Center for Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL), Switzerland, show that people can be "tricked" into feeling that an image of a human figure -- an "avatar" -- is their own body. The study is published in the open-access journal Frontiers in Behavioral Neuroscience.
Twenty-two volunteers underwent a Full Body Illusion when they were stroked with a robotic device system while they watched an avatar being stroked in the same spot. The study is the first to demonstrate that Full Body Illusions can be accompanied by changes ...
Doctors urged to talk to patients about parking cellphones
2013-07-30
(Edmonton) Family physicians regularly counsel patients about medical risks associated with heart disease, stroke, diabetes and smoking, and a team from the University of Alberta wants to add cellphone use and driving to the discussion.
Talking on a cellphone while driving raises the risk of collision by four to six times—comparable to getting behind the wheel while under the influence, studies show. Addressing the problem requires educating the public about the risks, and a good place to start is in the doctor's office.
"The evidence is clear and compelling. Epidemiologic, ...
Protein surfaces defects act as drug targets
2013-07-30
New research shows a physical characterisation of the interface of the body's proteins with water. Identifying the locations where it is easiest to remove water from the interface of target proteins could constitute a novel drug design strategy. The candidate drugs would need to be engineered to bind at the site of the protein where interfacial water is most easily dislodged. These findings, based on the work of María Belén Sierra from the National University of the South, in Bahia Blanca, Argentina and colleagues, were recently published in EPJ E.
The challenge is to ...
Researchers overcome technical hurdles in quest for inexpensive, durable electronics and solar cells
2013-07-30
Electronic touch pads that cost just a few dollars and solar cells that cost the same as roof shingles are one step closer to reality today.
Researchers in the University of Minnesota's College of Science and Engineering and the National Renewable Energy Laboratory in Golden, Colo., have overcome technical hurdles in the quest for inexpensive, durable electronics and solar cells made with non-toxic chemicals. The research was published in the most recent issue of Nature Communications, an international online research journal.
"Imagine a world where every child in a ...
Study shows combination stroke therapy safe and effective
2013-07-30
CINCINNATI -- The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.
Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals.
Standard treatment for acute ischemic stroke (characterized by an obstruction ...
Breast reduction surgery found to improve physical, mental well-being
2013-07-30
Philadelphia, Pa. (July 30, 2013) – Breast reduction surgery produces measurable improvements in several important areas of health and quality of life, reports a study in the August issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The study used the BREAST-Q© questionnaire, a well-validated survey instrument, to document the physical and psychosocial health benefits of breast reduction surgery. "The improvement in physical well-being is important for justification of insurance coverage," according ...
Hardness, in depth
2013-07-30
WASHINGTON D.C. -- In today's precision manufacturing environment, designers of products as diverse as car airbag sensors, computer microchips, drill bits and paint often need to know the mechanical properties of their materials' down to the nanometer scale. Scientists have now built a machine that sets a new standard of accuracy for testing one of those properties: a material's hardness, which is a measure of its resistance to bumps and scratches.
The new machine is called the Precision Nanoindentation Platform, or PNP. It was created in response to the need to test ...
LAST 30 PRESS RELEASES:
New perspective highlights urgent need for US physician strike regulations
An eye-opening year of extreme weather and climate
Scientists engineer substrates hostile to bacteria but friendly to cells
New tablet shows promise for the control and elimination of intestinal worms
Project to redesign clinical trials for neurologic conditions for underserved populations funded with $2.9M grant to UTHealth Houston
Depression – discovering faster which treatment will work best for which individual
Breakthrough study reveals unexpected cause of winter ozone pollution
nTIDE January 2025 Jobs Report: Encouraging signs in disability employment: A slow but positive trajectory
Generative AI: Uncovering its environmental and social costs
Lower access to air conditioning may increase need for emergency care for wildfire smoke exposure
Dangerous bacterial biofilms have a natural enemy
Food study launched examining bone health of women 60 years and older
CDC awards $1.25M to engineers retooling mine production and safety
Using AI to uncover hospital patients’ long COVID care needs
$1.9M NIH grant will allow researchers to explore how copper kills bacteria
New fossil discovery sheds light on the early evolution of animal nervous systems
A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior
Study shows how plant roots access deeper soils in search of water
Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs
‘What is that?’ UCalgary scientists explain white patch that appears near northern lights
How many children use Tik Tok against the rules? Most, study finds
Scientists find out why aphasia patients lose the ability to talk about the past and future
Tickling the nerves: Why crime content is popular
Intelligent fight: AI enhances cervical cancer detection
Breakthrough study reveals the secrets behind cordierite’s anomalous thermal expansion
Patient-reported influence of sociopolitical issues on post-Dobbs vasectomy decisions
Radon exposure and gestational diabetes
EMBARGOED UNTIL 1600 GMT, FRIDAY 10 JANUARY 2025: Northumbria space physicist honoured by Royal Astronomical Society
Medicare rules may reduce prescription steering
Red light linked to lowered risk of blood clots
[Press-News.org] Inhalable gene therapy may help pulmonary arterial hypertension patientsGene therapy when inhaled may restore function of a crucial enzyme in the lungs to reverse deadly PAH